CDY 4.11% 38.0¢ cellmid limited

News: Cellmid targets substantial sales growth in 2015

  1. A larger product range, increases to its pharmacy distribution and larger salon sales force are expected to deliver substantial sales growth for its consumer health business in 2015. The company is also progressing its lead humanised oncology anti-midkine antibody (CAB102) for use in solid tumours towards the next value inflection point.

 
watchlist Created with Sketch. Add CDY (ASX) to my watchlist
(20min delay)
Last
38.0¢
Change
0.02(4.11%)
Mkt cap $30.46M
Open High Low Value Volume
37.5¢ 38.0¢ 37.5¢ $9.492K 25.21K

Buyers (Bids)

No. Vol. Price($)
2 45000 36.5¢
 

Sellers (Offers)

Price($) Vol. No.
38.0¢ 2785 1
Last update - 15.41pm 15/10/2018 (20 minute delay) ?
(live)
Last
37.5¢
  Change
0.02 ( 4.17 %)
Open High   Low Volume
37.5¢ 37.5¢   37.5¢ 3400
Last updated 15.18pm 15/10/2018 (live) ?
CDY (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.